Joseph Selsavage - Sep 1, 2022 Form 3 Insider Report for 23andMe Holding Co. (ME)

Role
Interim CFO
Signature
/s/ Joseph Selsavage, by Kathy Hibbs, attorney-in-fact
Stock symbol
ME
Transactions as of
Sep 1, 2022
Transactions value $
$0
Form type
3
Date filed
9/2/2022, 04:00 PM
Next filing
Nov 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ME Class A Common Stock 158K Sep 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ME Stock Option (Right to Buy) Sep 1, 2022 Class A Common Stock 521K $0.96 Direct F1
holding ME Stock Option (Right to Buy) Sep 1, 2022 Class A Common Stock 80.5K $3.56 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received in the November 2021 merger in which the issuer acquired Lemonaid Health, Inc. ("Lemonaid Health") in exchange for an option to purchase 384,340 shares of common stock of Lemonaid Health. The stock options vest over a four-year period, with an initial 25% vesting on November 1, 2021, and the remainder vesting on a monthly basis thereafter.
F2 The stock options vest equally in 1/48 monthly installments beginning on May 1, 2022.